<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813383</url>
  </required_header>
  <id_info>
    <org_study_id>Celiac disease and HLA-DQ2.2</org_study_id>
    <nct_id>NCT01813383</nct_id>
  </id_info>
  <brief_title>Clinical Relevance of Typing HLA-DR7-DQ2</brief_title>
  <acronym>HLA</acronym>
  <official_title>Clinical Relevance of Typing HLA-DR7-DQ2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Celiac disease patients with HLA-DR7-DQ2 haplotype have the same histological, analytical and
      clinical behaviour as patients with HLA-DR3-DQ2 haplotype.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tissue transglutaminase</measure>
    <time_frame>Up to 1 month after diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Endomysium autoantibodies</measure>
    <time_frame>Up to 1 month after diagnosis</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Oberhuber histological damage classification</measure>
    <time_frame>Up to 1 month after diagnosis</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristics of celiac disease</measure>
    <time_frame>Up to 1 month after diagnosis</time_frame>
    <description>Asymptomatic, intestinal symptoms, extra-intestinal symptoms, European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) score</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">92</enrollment>
  <condition>Celiac Disease Patients Following Recommendations of ESPGHAN</condition>
  <condition>HLA-DQ2 Typing Include HLA-DR7-DQ2 Haplotypes</condition>
  <arm_group>
    <arm_group_label>HLA-DR3-DQ2 patients</arm_group_label>
    <description>Patients with HLA-DR3-DQ2 haplotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLA-DR7-DQ2 patients</arm_group_label>
    <description>Patients with HLA-DR7-DQ2 haplotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is not any intervention</intervention_name>
    <arm_group_label>HLA-DR3-DQ2 patients</arm_group_label>
    <arm_group_label>HLA-DR7-DQ2 patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Celiac disease patients who have been diagnosed in a Hospital by a Pediatrician.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of celiac disease following ESPGHAN recommendations

          -  HLA-DQ2 typing including HLA-DR3-DQ2 and HLA-DR7-DQ2 haplotypes

        Exclusion Criteria:

          -  Patients who have not been diagnosed for celiac disease

          -  HLA-DQ2 typing that not include HLA-DR7-DQ2 haplotype
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Francisco Delgado de la Poza</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunology Section, Laboratori. UDIAT-CD. Corporació Sanitària i Universitària Parc Taulí</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Corporació Sanitària i Universitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Juan Francisco Delgado de la Poza</investigator_full_name>
    <investigator_title>Medicine. Immunology specialist</investigator_title>
  </responsible_party>
  <keyword>Celiac disease</keyword>
  <keyword>HLA-DQ2.2</keyword>
  <keyword>HLA-DQ2.5</keyword>
  <keyword>HLA-DR7-DQ2</keyword>
  <keyword>HLA-DR3-DQ2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

